Cancer Research

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Callio Therapeutics #Financing #Oncology #Start-ups

$187m supports a new generation of ADC therapies

Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round.   Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.  The newly formed company, with headquarters in Seattle and Singapore,… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Interview #Kite Pharma #Oncology

CAR-T cell therapy: Overcoming critical infrastructure challenges 

DDW’s Diana Spencer speaks to Dan Tovar, Senior Director, Head of Cell Therapy ACE Midsize Markets, Medical Affairs at Kite Pharma, about the current landscape for cell therapies and what can be done to improve patient access.  DS: Kite has pioneered cell therapy, with Yescarta (axicabtagene ciloleucel) as… Read More

#Business & Investment #Cancer Research #Exclusive Content

Doctor points at child's brain scan
#Australia #Brain cancer #Checkpoint inhibitor therapies #Immunotherapy #Oncology #University of Sydney

Study shows potential for triple immunotherapy in glioblastoma

An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.  It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More

#Cancer Research #News #Trending News

#Immuno-oncology #Immunotherapy #Oncology #Personalised medicine

Navigating the landscape of immunotherapy

Giusy Di Conza, Head of Research at iOnctura, explores the challenges of current immunotherapy approaches for cancer and where opportunity lies. Immunotherapy has transformed modern oncology. Immune checkpoint inhibitors like pembrolizumab and nivolumab revolutionised melanoma treatment by enhancing immune responses; ensuring it could become a manageable disease – with improved… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell manufacturing #Cell therapy #Oncology

Bringing CAR-T cell production closer to patients

Dr Liping Yu, Vice President of Applications at Applied Cells, looks at barriers to access for CAR-T cell therapies. CAR-T cell therapies are increasingly being used to treat life-threatening conditions when other treatments have failed, particularly in oncology. Autologous CAR-T cancer therapies involve isolating T cells from a patient’s blood,… Read More

#Cancer Research #Exclusive Content

CRISPR Cas9
#Brain cancer #CRISPR #CRISPR screening #Oncology #The Institute of Cancer Research

CRISPR reveals new therapeutic target for glioblastoma

Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma rely on transforming growth factor beta-activated kinase 1 (TAK1) for survival and that inhibiting this enzyme leads to the death of the cells.  Furthermore, they have demonstrated that it is… Read More

#Cancer Research #News #Trending News

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

Myeloma cells
#Genetics #Myeloma #Oncology #Personalised medicine #The Institute of Cancer Research

Personalised treatment needed for high-risk myeloma, say scientists

Offering genetic testing to patients with myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted more effectively, say scientists.  With effective treatment, more than half of myeloma patients will survive their disease for five years… Read More

#Cancer Research #Editor's Choice #News

The extracellular matrix
#Barts Institute #Oncology #The Institute of Cancer Research #Tumour microenvironment (TME)

Cancer breakthrough could stop tumours before they metastasise

Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body.  The research, published in Nature Communications, reveals how cancer cells are altered by their surroundings, enabling them to change their… Read More

#Cancer Research #News #Trending News

Melanoma or skin cancer
#Immunotherapy #Oncology #Skin cancer #University of Queensland

Cancer immunotherapy reduces skin cancers by 65%

University of Queensland researchers have discovered that immunotherapy, when used to treat people with advanced cancers, also helps reduce sunspots and skin cancers by at least 65%.  Over 12 months, researchers monitored 23 patients receiving immunotherapy for unrelated cancers and found the treatment also targeted cancerous and… Read More

#Cancer Research #News

Scientist using a laptop
#Cancer Research Horizons #Laboratory data #Lifebit #Oncology

Partnership will open access to millions of cancer datasets

Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research.   This federated network uses Lifebit’s Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in… Read More

#Cancer Research #News

Neurons
#Lung cancer #Oncology #Small cell lung cancer #The Francis Crick Institute

Lung cancer cells build their own electrical network 

Researchers from the Francis Crick Institute have found that aggressive lung cancer cells can develop their own electric network, like that seen in the nervous system.  This unique property could make them less dependent on the environment surrounding the tumour and even spread more easily, say the… Read More

#Cancer Research #News #Trending News

Breast cancer
#AstraZeneca #Breast cancer #Cancer research #NHS Scotland #Scottish Medicines Consortium (SMC)

SMC accepts AstraZeneca’s breast cancer treatment

AstraZeneca’s Lynparza (olaparib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) to treat adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy. Breast cancer prevalence In Scotland, nearly 5,000 people are diagnosed with breast cancer each… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Cancer therapeutics #Drug repurposing #ETH Zurich #Oncology

Digoxin prevents breast cancer metastases in a new study

The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood, new research has found.  These clusters are responsible for the formation of metastases in other organs. The smaller the clusters, the fewer metastases… Read More

#Cancer Research #Editor's Choice #News

#2025 predictions #Cancer #Cancer research #Drug discovery

Cancer burden and research: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience. Here, looking at cancer burden and research in the sector. Ahead of World Cancer Day… Read More

#Business & Investment #Cancer Research #Exclusive Content #Trends & Analysis